ir.unither

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free ( DPF) facility, The Dr. Bartley P. Griffith and Dr.
ir.unither

United Therapeutics Statement on Settlement Agreement with Liquidia Technologies

United Therapeutics moved quickly over the last week to reach a settlement agreement with Liquidia Technologies, Inc. that enables continuity of therapy for all patients with pulmonary arterial ...
ir.unither

United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting

A pre-specified subgroup analysis from the phase 3 ADVANCE OUTCOMES study showed that ralinepag reduced the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH), ...
ir.unither

United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug ...
ir.unither

United Therapeutics Announces FDA Approval of Tyvaso DPI™

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the U.S. Food and Drug ...
ir.unither

Martine Rothblatt is Featured in Forbes Magazine's Special Centennial Issue as one of The World's 100 Greatest Living Business Minds

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2017 /PRNewswire/ -- Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics Corporation (NASDAQ: UTHR) is ...
ir.unither

United Therapeutics to Announce Third Quarter 2007 Financial Results Before Market Open on Thursday, November 1, 2007

SILVER SPRING, Md., Oct. 25 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its 2007 third quarter ...
ir.unither

United Therapeutics Repurchases 766,666 Shares of Its Common Stock From Toray Industries

SILVER SPRING, Md., July 27 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that it repurchased an aggregate of 766,666 ...
ir.unither

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

The TETON-PPF study is a 754-patient, multinational, randomized, double-blind, placebo-controlled phase 3 registration study to evaluate the safety and efficacy of nebulized Tyvaso in subjects with ...
ir.unither

United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering ...

The phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint and several important secondary endpoints, including increasing odds of clinical improvement by 47%, in predominantly ...
ir.unither

United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the ...